181 related articles for article (PubMed ID: 28072973)
21.
Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
[TBL] [Abstract][Full Text] [Related]
22. Outcome of pure mucinous breast carcinoma compared to infiltrating ductal carcinoma: a population-based study from China.
Cao AY; He M; Liu ZB; Di GH; Wu J; Lu JS; Liu GY; Shen ZZ; Shao ZM
Ann Surg Oncol; 2012 Sep; 19(9):3019-27. PubMed ID: 22451233
[TBL] [Abstract][Full Text] [Related]
23. [Relationship of oncogene C-erbB2 expression to ER, PR and PS2 in breast cancer and its prognostic significance].
Yang JQ; Chen L; Xing TY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 May; 35(3):334-6, 357. PubMed ID: 15181828
[TBL] [Abstract][Full Text] [Related]
24. HPK1 positive expression associated with longer overall survival in patients with estrogen receptor-positive invasive ductal carcinoma‑not otherwise specified.
Wang J; Song L; Yang S; Zhang W; Lu P; Li S; Li H; Wang L
Mol Med Rep; 2017 Oct; 16(4):4634-4642. PubMed ID: 28765906
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma.
Zhao P; Lu Y; Jiang X; Li X
Cancer Sci; 2011 May; 102(5):1107-11. PubMed ID: 21276138
[TBL] [Abstract][Full Text] [Related]
26. [Differences and clinical significance of receptor expression between primary and locally recurrent breast tumor tissues].
Ma XM; Han YW; Zhang J; Cui WJ; Wang X
Zhonghua Zhong Liu Za Zhi; 2013 May; 35(5):372-6. PubMed ID: 24054015
[TBL] [Abstract][Full Text] [Related]
27. Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.
Subramaniam S; Bhoo-Pathy N; Taib NA; Tan GH; See MH; Jamaris S; Ho GF; Looi LM; Yip CH
World J Surg; 2015 Oct; 39(10):2450-8. PubMed ID: 26138872
[TBL] [Abstract][Full Text] [Related]
28. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
[TBL] [Abstract][Full Text] [Related]
29. Expression of calretinin in high-grade hormone receptor-negative invasive breast carcinomas: correlation with histological and molecular subtypes.
Micello D; Bossi A; Marando A; Dainese E; Sessa F; Capella C
Virchows Arch; 2017 Jul; 471(1):13-21. PubMed ID: 28550498
[TBL] [Abstract][Full Text] [Related]
30. Invasive micropapillary carcinoma of the breast: a clinicopathologic study of 103 cases of an unusual and highly aggressive variant of breast carcinoma.
Gokce H; Durak MG; Akin MM; Canda T; Balci P; Ellidokuz H; Demirkan B; Gorken IB; Sevinc AI; Kocdor MA; Saydam S; Harmancioglu O
Breast J; 2013; 19(4):374-81. PubMed ID: 23714006
[TBL] [Abstract][Full Text] [Related]
31. [Analysis of BCRP expression in breast cancer patients].
Maciejczyk A; Szelachowska J; Ekiert M; Matkowski R; Hałoń A; Surowiak P
Ginekol Pol; 2012 Sep; 83(9):681-7. PubMed ID: 23342897
[TBL] [Abstract][Full Text] [Related]
32. [Relationship between breast cancer molecular subtypes with clinicopathological characteristics and prognosis].
Lin M; Chen ZQ; Bao Y; Li Q; Du ZG; Xu ZD; Tang F
Zhonghua Bing Li Xue Za Zhi; 2010 Jun; 39(6):372-6. PubMed ID: 21055152
[TBL] [Abstract][Full Text] [Related]
33. [Comparison of histopathologic changes and expression of biomarkers in breast carcinoma before and after neoadjuvant chemotherapy].
Zheng S; Zhang BL; Xiao T; Zou SM; Xue LY; Luo W; Guo L; Liu XY; Lü N
Zhonghua Bing Li Xue Za Zhi; 2011 Jul; 40(7):465-70. PubMed ID: 22088373
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathologic characteristics and prognostic factors in patients with operable HER-2 overexpressing breast cancer.
Liu AN; Sun P; Liu JN; Ma JB; Qu HJ; Zhu H; Yu CY; Zhang LM
Asian Pac J Cancer Prev; 2012; 13(4):1197-201. PubMed ID: 22799305
[TBL] [Abstract][Full Text] [Related]
35. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
36. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
37. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
[TBL] [Abstract][Full Text] [Related]
38. Heat shock protein 27 and gross cystic disease fluid protein 15 play critical roles in molecular apocrine breast cancer.
Liu X; Feng C; Liu J; Zhao L; Liu J; Zhang W; Liu N; Niu Y
Tumour Biol; 2016 Jun; 37(6):8027-36. PubMed ID: 26711786
[TBL] [Abstract][Full Text] [Related]
39. [Clinicopathologic analysis of the nipple-areolar complex occult involvement in early stage breast carcinoma].
Wang SY; Peng DF; Cai ZG; Zhang RZ; Yao TJ; Zhang H; Yang M; Dong HM
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):203-6. PubMed ID: 18756937
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of preoperative
Higuchi T; Nishimukai A; Ozawa H; Fujimoto Y; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Kitajima K; Fukushima K; Miyoshi Y
Breast; 2016 Dec; 30():5-12. PubMed ID: 27569020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]